ZELLUNA IMMUNOTHERAPY
Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on the development of TCR based immunotherapies. Our goal is to revolutionize cancer therapy by developing TCR based therapies with the potential to treat a wide range of cancer types and patients. Zelluna’s core asset is a wide range of TCRs isolated from patients who exhibited long-term survival following inclusion in peptide based cancer vaccine trials initiated by Prof Gustav Gaudern... ack and conducted by investigators at the Norwegian Radium Hospital/Oslo University Hospital. Currently the company has several TCRs in different stages of development. We are a member of Oslo Cancer Cluster (Norwegian Centre of Expertise), a member organization for Norwegian and International stakeholders within cancer research and development. Oslo Cancer Cluster has members from the biotechnology industry, the government, patient organizations, research institutions and hospitals. Zelluna is located at the Oslo Cancer Cluster Innovation Park, next to the Norwegian Radium Hospital/Oslo University Hospital, the Department for Cellular Therapy and one of Europe’s largest academic certified GMP facilities for cellular products.
ZELLUNA IMMUNOTHERAPY
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2016-01-01
Address:
Oslo, Oslo, Norway
Country:
Norway
Website Url:
http://www.zelluna.com
Total Employee:
11+
Status:
Active
Contact:
47 22 84 00 80
Email Addresses:
[email protected]
Total Funding:
7.5 M EUR
Technology used in webpage:
Euro CrUX Dataset CrUX Top 10m
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Adrenomed
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
BAV Institut
BAV Institut is a testing laboratory for food, cosmetics, and pharmaceutical companies.
Built by Doctors
Built by Doctors specializes in developing medical support guides for pharmaceutical companies.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Takeda Ventures
Takeda Ventures investment in Venture Round - Zelluna Immunotherapy
Birk Venture
Birk Venture investment in Seed Round - Zelluna Immunotherapy
Key Employee Changes
| Date | New article |
|---|---|
| 2019-12-19 | Zelluna Immunotherapy appoints new chief executive |
Official Site Inspections
http://www.zelluna.com Semrush global rank: 11.53 M Semrush visits lastest month: 156
- Host name: webwash01.clh.no
- IP address: 91.220.196.231
- Location: Norway
- Latitude: 59.9452
- Longitude: 10.7559
- Timezone: Europe/Oslo
More informations about "Zelluna Immunotherapy"
Zelluna Immunotherapy - Crunchbase Company Profile & Funding
Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on the development of TCR based immunotherapies. ... (Norwegian Centre of …See details»
Management - Zelluna Immunotherapy AS
Prior to joining Zelluna, Namir was a VP at Immunocore, responsible for creating and growing the infectious disease unit and pipeline as well as helping to secure up to $40M of funding for the …See details»
Zelluna Immunotherapy Company Profile 2024: …
Zelluna Immunotherapy General Information Description. Operator of a biopharmaceutical company intended to develop T-cell receptor (TCR) based cancer immunotherapy. The company's primary focus is to develop a portfolio …See details»
Zelluna Immunotherapy: Contact Details and Business Profile
Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The …See details»
Zelluna Immunotherapy - LinkedIn
Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers.See details»
Zelluna Immunotherapy - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Zelluna Immunotherapy - Updates, News, Events, Signals & Triggers
Zelluna Immunotherapy will present at the 9th Annual Innate Killer Summit in 2024, highlighting its engagement in significant industry events. Additionally, a key board member, serving since …See details»
Zelluna Immunotherapy - Leadership Team - The Org
The Leadership Team at Zelluna Immunotherapy is responsible for setting the strategic direction of the company, overseeing operations, and driving business development initiatives. …See details»
Zelluna Immunotherapy - Overview, News & Similar companies
Who is Zelluna Immunotherapy. Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell …See details»
Zelluna Immunotherapy - Company Profile - Tracxn
Nov 5, 2024 Zelluna Immunotherapy ranks 603rd among 2486 active competitors. 897 of its competitors are funded while 574 have exited. Overall, Zelluna Immunotherapy and its …See details»
Zelluna Immunotherapy - BIO International Convention | BIO
Jun 5, 2023 Zelluna's pipeline consists of programs targeting TCR antigens shown clinically to be viable targets for a broad range of solid cancers (e.g MAGE-A4 and PRAME). Zelluna is …See details»
Zelluna - Oslo Cancer Cluster - Innovation Park
Zelluna’s core asset is a wide range of TCRs isolated from patients who exhibited long-term survival following inclusion in peptide based cancer vaccine trials initiated by Prof Gustav …See details»
Zelluna Immunotherapy - Craft
Zelluna Immunotherapy has 5 employees at their 1 location and $8.51 m in total funding,. See insights on Zelluna Immunotherapy including office locations, competitors, revenue, financials, …See details»
About Zelluna - Zelluna Immunotherapy AS
The Zelluna Academy was established to represent the various programs and activities intended to support continuous learning and development for individuals and teams across the …See details»
Zelluna - EU-Startups
Zelluna’s core asset is a wide range of TCRsisolated from patients who exhibited long-term survival following inclusion in peptide-based cancer vaccine trials initiated by Prof Gustav …See details»
Zelluna Immunotherapy appoints Namir Has... - Zelluna …
Namir joined Zelluna as CSO from Immunocore Ltd where he was responsible for building the biology, preclinical and biomarker organizations in oncology. ... Previously, Namir had a …See details»
Zelluna Immunotherapy - Products, Competitors, Financials, …
Zelluna Immunotherapy announces investment from Takeda Ventures, Inc. Aug 26, 2022. Zelluna Immunotherapy announces investment from Takeda Ventures, Inc. Zelluna Immunotherapy …See details»
Exclusive License Agreement with the U.S... - Zelluna …
Under the agreement Zelluna will have exclusive rights from the NCI to use the well characterized KK-LC-1 TCR for the development and commercialization of a TCR-NK product. TCR-NK …See details»
Pipeline - Zelluna Immunotherapy AS
Zelluna is developing TCR based cellular immunotherapy products for the treatment of solid tumors. Our current pipeline consists of allogeneic TCR-NK R&D programs targeting well …See details»